ESMO 24: Replimune’s Cancer Vaccine Succeeds In PD-1 Failures

New data suggest that RP1 could become the therapy of choice in melanoma patients who do not respond to checkpoint inhibitors.    

Medical concept Vaccination vaccine vial dose flu shot drug needle syringe,Lab test research science hypodermic injection treatment disease care hospital prevention immunization illness disease baby.

Checkpoint inhibitors have revolutionized cancer treatment, but they aren’t perfect, and there is a niche for therapies to treat those whose disease progresses despite receiving these therapies. Replimune Group Inc. believes its cancer vaccine RP1 (vusolimogene oderparepvec) could become the go-to option for melanoma patients in this situation following an impressive update from the IGNYTE trial.

More from Clinical Trials

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By 

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.

Cassava At Crossroads As Simufilam Finally Exits, Stage Left

 

The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.

Sanofi Nabs Priority Review For MS Drug Tolebrutinib

 
• By 

A decision from the FDA is due by 28 September.

Novo Gets Its Own ‘Triple G’ Obesity Drug To Rival Lilly

 

The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.

More from R&D